252 related articles for article (PubMed ID: 23804506)
1. Evidence synthesis for decision making 1: introduction.
Dias S; Welton NJ; Sutton AJ; Ades AE
Med Decis Making; 2013 Jul; 33(5):597-606. PubMed ID: 23804506
[TBL] [Abstract][Full Text] [Related]
2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
3. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
5. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
6. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
9. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
10. Evidence synthesis for decision making 7: a reviewer's checklist.
Ades AE; Caldwell DM; Reken S; Welton NJ; Sutton AJ; Dias S
Med Decis Making; 2013 Jul; 33(5):679-91. PubMed ID: 23804511
[TBL] [Abstract][Full Text] [Related]
11. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
12. An exploration of synthesis methods in public health evaluations of interventions concludes that the use of modern statistical methods would be beneficial.
Achana F; Hubbard S; Sutton A; Kendrick D; Cooper N
J Clin Epidemiol; 2014 Apr; 67(4):376-90. PubMed ID: 24388291
[TBL] [Abstract][Full Text] [Related]
13. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
14. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
Schlander M
J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
[TBL] [Abstract][Full Text] [Related]
16. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
17. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
18. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
Davies E; Littlejohns P
J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
[TBL] [Abstract][Full Text] [Related]
19. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
